TITLE

Recently Approved

PUB. DATE
February 2007
SOURCE
Pharmaceutical Representative;Feb2007, Vol. 37 Issue 2, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the drugs approved by the U.S. Food and Drug Administration (FDA) in 2007. They include Celebrex from Pfizer Inc., ulcerative colitis drug Colazal from Salix Pharmaceuticals Inc., and NitroMist from NovaDel Pharma Inc. Information about each drug and their approval by the FDA are briefly discussed.
ACCESSION #
23970926

 

Related Articles

  • FDA Actions. Elliott, William T. // Neurology Alert;Jun2010 Primary Care, Vol. 15 Issue 6, p2 

    The article reports on new drug approvals made by the U.S. Food and Drug Administration (FDA) as of June 2010 including Salix Pharmaceutical's minimally absorbed oral antibiotic called Rifaximin, another drug called Pancreaze and the first generic version of the antihypertensive losartan and the...

  • FDA Actions. Elliott, William T. // Alternative Medicine Alert;Jun2010 Supplement, p2 

    The article reports on new drug approvals made by the U.S. Food and Drug Administration (FDA) as of June 2010 including Salix Pharmaceutical's minimally absorbed oral antibiotic called Rifaximin, another drug called Pancreaze and the first generic version of the antihypertensive losartan and the...

  • SALIX PHARMACEUTICALS receives FDA nod for Xifaxan 550 mg.  // TendersInfo News;5/30/2015, p1 

    The article reports that Xifaxan 550 mg drug developed by Valeat ant Pharmaceuticals International Inc.'s wholly owned subsidiary, Salix Pharmaceuticals Ltd. for the treatment of Irritable Bowel Syndrome with Diarrhea or IBS-D in adults has been approved by the U.S. Food and Drug Administration...

  • Lower doses for certain zolpidem-containig drugs. Fine, Anna M.; Miller, Cathy // Pharmacy Today;Mar2013, Vol. 19 Issue 3, p46 

    The article reports that the U.S. Food and Drug Administration (FDA) warned health professionals in January 2013 on the risk of insomnia drugs that contain zolpidem. It says that DFA alerted health professionals to caution patients who use products with zolpidem on the risks of next-morning...

  • NovaDel Reports Opening of Duromist(tm) original IND with FDA.  // Biomedical Market Newsletter;6/9/2011, p922 

    The article focuses on the report of NovaDel Pharma Inc. on the opening of an original Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead development program Duromist (tm). Chief executive officer (CEO) Steven B. Ratoff says that an important...

  • CELEBREX UPDATE.  // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p21 

    Reports that the U.S. Food and Drug Administration has approved a blackbox warning for Pfizer Inc.'s arthritis pain drug Celebrex, highlighting the increased risk of cardiovascular events associated with the product. Agency's call on Pfizer to include a medication guide and conduct a long-term...

  • NEWS.  // Pharmaceutical Technology Europe;Feb2005, Vol. 17 Issue 2, p8 

    The article presents news on various developments in the pharmaceutical technology industry. The article reports that following Merck Co.'s decision to withdraw its blockbuster COX-2 Vioxx (rofecoxib) from the market and Pfizer's concerns regarding its Celebrex, the U.S. FDA is set to determine...

  • A late call.  // Advertising Age;5/10/1999, Vol. 70 Issue 10, p36 

    Questions the efforts of the U.S. Food & Drug Administration (FDA) to convince Pfizer and G. D. Searle & Co. to change the name of a new anti-arthritis medication called Celebrex after the agency received complaints about consumer confusion between the said drug and other drugs. Claim of the...

  • COLAZAL "FOOD EFFECT" APPLICATION GRANTED FDA APPROVAL.  // Biotech Business;Nov2006, Vol. 19 Issue 11, p8 

    The article reports on the approved labeling for colazal from Salix Pharmaceuticals, Ltd. in North Carolina. Labeling for colazal, an anti-inflammatory drug for active ulcerative colitis, was approved by the U.S. Food and Drug Administration. The nature of Salix Pharmaceuticals and implications...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics